Development of a predictive algorithm for the efficacy of half-life extension strategies

[Display omitted] A challenge in development of peptide and protein therapeutics is rapid elimination from the body, necessitating frequent dosing that may lead to toxicities and/or poor patient compliance. To solve this issue, there has been great investment into half-life extension of rapidly elim...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2024-07, Vol.660, p.124382, Article 124382
1. Verfasser: Glassman, Patrick M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 124382
container_title International journal of pharmaceutics
container_volume 660
creator Glassman, Patrick M.
description [Display omitted] A challenge in development of peptide and protein therapeutics is rapid elimination from the body, necessitating frequent dosing that may lead to toxicities and/or poor patient compliance. To solve this issue, there has been great investment into half-life extension of rapidly eliminated drugs using approaches such as albumin binding, fusion to albumin or Fc, or conjugation to polyethylene glycol. Despite clinical successes of half-life extension products, no clear relationship has been drawn between properties of drugs and the pharmacokinetic parameters of their half-life extended analogues. In this study, non-compartmentally derived pharmacokinetic parameters (half-life, clearance, volume of distribution) were collected for 186 half-life extended drugs and their unmodified parent molecules. Statistical testing and regression analysis was performed to evaluate relationships between pharmacokinetic parameters and a matrix of variables. Multivariate linear regression models were developed for each of the three pharmacokinetic parameters and model predictions were in good agreement with observed data with r2 values for each parameter being: half-life: 0.879, clearance: 0.820, volume of distribution: 0.937. Significant predictors for each parameter included the corresponding pharmacokinetic parameter of the parent drug and descriptors related to molecular weight. This model represents a useful tool for prediction of the potential benefits of half-life extension.
doi_str_mv 10.1016/j.ijpharm.2024.124382
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3072291073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517324006161</els_id><sourcerecordid>3072291073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-4ec08eb45645cef1a7c2e19716951a14fb2532e1fe0d5aee5910884eee9261303</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMotlYfQZmlm6m5TCYzKxHvUHCj4C6kmZM2ZWYyJmmxb29Kq1tXBw7ffy4fQpcETwkm5c1qalfDUvluSjEtpoQWrKJHaEwqwXJWiPIYjTETVc6JYCN0FsIKY1xSwk7RiFU1ETWvx-jzATbQuqGDPmbOZCobPDRWR7uBTLUL521cdplxPotLyMAYq5Xe7tClak3eWpO63xH6YF2fhehVhIWFcI5OjGoDXBzqBH08Pb7fv-Szt-fX-7tZrtPFMS9A4wrmBS8LrsEQJTQFUgtS1pwoUpg55Sx1DOCGKwBeE1xVBQDUtCQMswm63s8dvPtaQ4iys0FD26oe3DpIhgWlKSRYQvke1d6F4MHIwdtO-a0kWO6kypU8SJU7qXIvNeWuDivW8w6av9SvxQTc7gFIj24seBm0hV4nkR50lI2z_6z4AVoii1E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072291073</pqid></control><display><type>article</type><title>Development of a predictive algorithm for the efficacy of half-life extension strategies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Glassman, Patrick M.</creator><creatorcontrib>Glassman, Patrick M.</creatorcontrib><description>[Display omitted] A challenge in development of peptide and protein therapeutics is rapid elimination from the body, necessitating frequent dosing that may lead to toxicities and/or poor patient compliance. To solve this issue, there has been great investment into half-life extension of rapidly eliminated drugs using approaches such as albumin binding, fusion to albumin or Fc, or conjugation to polyethylene glycol. Despite clinical successes of half-life extension products, no clear relationship has been drawn between properties of drugs and the pharmacokinetic parameters of their half-life extended analogues. In this study, non-compartmentally derived pharmacokinetic parameters (half-life, clearance, volume of distribution) were collected for 186 half-life extended drugs and their unmodified parent molecules. Statistical testing and regression analysis was performed to evaluate relationships between pharmacokinetic parameters and a matrix of variables. Multivariate linear regression models were developed for each of the three pharmacokinetic parameters and model predictions were in good agreement with observed data with r2 values for each parameter being: half-life: 0.879, clearance: 0.820, volume of distribution: 0.937. Significant predictors for each parameter included the corresponding pharmacokinetic parameter of the parent drug and descriptors related to molecular weight. This model represents a useful tool for prediction of the potential benefits of half-life extension.</description><identifier>ISSN: 0378-5173</identifier><identifier>ISSN: 1873-3476</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2024.124382</identifier><identifier>PMID: 38917959</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Algorithms ; Drug delivery ; Half-Life ; Half-life extension ; Humans ; Linear Models ; Models, Biological ; Multivariate regression ; Pharmaceutical Preparations - administration &amp; dosage ; Pharmaceutical Preparations - chemistry ; Pharmaceutical Preparations - metabolism ; Pharmacokinetics</subject><ispartof>International journal of pharmaceutics, 2024-07, Vol.660, p.124382, Article 124382</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-4ec08eb45645cef1a7c2e19716951a14fb2532e1fe0d5aee5910884eee9261303</cites><orcidid>0000-0003-3786-0437</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2024.124382$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38917959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glassman, Patrick M.</creatorcontrib><title>Development of a predictive algorithm for the efficacy of half-life extension strategies</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] A challenge in development of peptide and protein therapeutics is rapid elimination from the body, necessitating frequent dosing that may lead to toxicities and/or poor patient compliance. To solve this issue, there has been great investment into half-life extension of rapidly eliminated drugs using approaches such as albumin binding, fusion to albumin or Fc, or conjugation to polyethylene glycol. Despite clinical successes of half-life extension products, no clear relationship has been drawn between properties of drugs and the pharmacokinetic parameters of their half-life extended analogues. In this study, non-compartmentally derived pharmacokinetic parameters (half-life, clearance, volume of distribution) were collected for 186 half-life extended drugs and their unmodified parent molecules. Statistical testing and regression analysis was performed to evaluate relationships between pharmacokinetic parameters and a matrix of variables. Multivariate linear regression models were developed for each of the three pharmacokinetic parameters and model predictions were in good agreement with observed data with r2 values for each parameter being: half-life: 0.879, clearance: 0.820, volume of distribution: 0.937. Significant predictors for each parameter included the corresponding pharmacokinetic parameter of the parent drug and descriptors related to molecular weight. This model represents a useful tool for prediction of the potential benefits of half-life extension.</description><subject>Algorithms</subject><subject>Drug delivery</subject><subject>Half-Life</subject><subject>Half-life extension</subject><subject>Humans</subject><subject>Linear Models</subject><subject>Models, Biological</subject><subject>Multivariate regression</subject><subject>Pharmaceutical Preparations - administration &amp; dosage</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Pharmaceutical Preparations - metabolism</subject><subject>Pharmacokinetics</subject><issn>0378-5173</issn><issn>1873-3476</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKAzEUhoMotlYfQZmlm6m5TCYzKxHvUHCj4C6kmZM2ZWYyJmmxb29Kq1tXBw7ffy4fQpcETwkm5c1qalfDUvluSjEtpoQWrKJHaEwqwXJWiPIYjTETVc6JYCN0FsIKY1xSwk7RiFU1ETWvx-jzATbQuqGDPmbOZCobPDRWR7uBTLUL521cdplxPotLyMAYq5Xe7tClak3eWpO63xH6YF2fhehVhIWFcI5OjGoDXBzqBH08Pb7fv-Szt-fX-7tZrtPFMS9A4wrmBS8LrsEQJTQFUgtS1pwoUpg55Sx1DOCGKwBeE1xVBQDUtCQMswm63s8dvPtaQ4iys0FD26oe3DpIhgWlKSRYQvke1d6F4MHIwdtO-a0kWO6kypU8SJU7qXIvNeWuDivW8w6av9SvxQTc7gFIj24seBm0hV4nkR50lI2z_6z4AVoii1E</recordid><startdate>20240720</startdate><enddate>20240720</enddate><creator>Glassman, Patrick M.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3786-0437</orcidid></search><sort><creationdate>20240720</creationdate><title>Development of a predictive algorithm for the efficacy of half-life extension strategies</title><author>Glassman, Patrick M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-4ec08eb45645cef1a7c2e19716951a14fb2532e1fe0d5aee5910884eee9261303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Algorithms</topic><topic>Drug delivery</topic><topic>Half-Life</topic><topic>Half-life extension</topic><topic>Humans</topic><topic>Linear Models</topic><topic>Models, Biological</topic><topic>Multivariate regression</topic><topic>Pharmaceutical Preparations - administration &amp; dosage</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Pharmaceutical Preparations - metabolism</topic><topic>Pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glassman, Patrick M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glassman, Patrick M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a predictive algorithm for the efficacy of half-life extension strategies</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2024-07-20</date><risdate>2024</risdate><volume>660</volume><spage>124382</spage><pages>124382-</pages><artnum>124382</artnum><issn>0378-5173</issn><issn>1873-3476</issn><eissn>1873-3476</eissn><abstract>[Display omitted] A challenge in development of peptide and protein therapeutics is rapid elimination from the body, necessitating frequent dosing that may lead to toxicities and/or poor patient compliance. To solve this issue, there has been great investment into half-life extension of rapidly eliminated drugs using approaches such as albumin binding, fusion to albumin or Fc, or conjugation to polyethylene glycol. Despite clinical successes of half-life extension products, no clear relationship has been drawn between properties of drugs and the pharmacokinetic parameters of their half-life extended analogues. In this study, non-compartmentally derived pharmacokinetic parameters (half-life, clearance, volume of distribution) were collected for 186 half-life extended drugs and their unmodified parent molecules. Statistical testing and regression analysis was performed to evaluate relationships between pharmacokinetic parameters and a matrix of variables. Multivariate linear regression models were developed for each of the three pharmacokinetic parameters and model predictions were in good agreement with observed data with r2 values for each parameter being: half-life: 0.879, clearance: 0.820, volume of distribution: 0.937. Significant predictors for each parameter included the corresponding pharmacokinetic parameter of the parent drug and descriptors related to molecular weight. This model represents a useful tool for prediction of the potential benefits of half-life extension.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38917959</pmid><doi>10.1016/j.ijpharm.2024.124382</doi><orcidid>https://orcid.org/0000-0003-3786-0437</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2024-07, Vol.660, p.124382, Article 124382
issn 0378-5173
1873-3476
1873-3476
language eng
recordid cdi_proquest_miscellaneous_3072291073
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Algorithms
Drug delivery
Half-Life
Half-life extension
Humans
Linear Models
Models, Biological
Multivariate regression
Pharmaceutical Preparations - administration & dosage
Pharmaceutical Preparations - chemistry
Pharmaceutical Preparations - metabolism
Pharmacokinetics
title Development of a predictive algorithm for the efficacy of half-life extension strategies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A31%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20predictive%20algorithm%20for%20the%20efficacy%20of%20half-life%20extension%20strategies&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Glassman,%20Patrick%20M.&rft.date=2024-07-20&rft.volume=660&rft.spage=124382&rft.pages=124382-&rft.artnum=124382&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2024.124382&rft_dat=%3Cproquest_cross%3E3072291073%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3072291073&rft_id=info:pmid/38917959&rft_els_id=S0378517324006161&rfr_iscdi=true